SK Life Science Inc.

Mar 10, 2020

SK life science Receives Schedule V Designation from DEA for XCOPRI® (cenobamate tablets)

Dec 06, 2019

SK life science to Present Latest Cenobamate Data at the American Epilepsy Society 2019 Annual Meeting

Dec 02, 2019

SK Life Science, Inc. Announces FDA Acceptance of IND Application for Anti-Epileptic Drug Candidate SKL24741

Jul 17, 2019

SK life science Expands Support for the J. Kiffin Penry Epilepsy Education Programs to Reach More Healthcare Providers

May 03, 2019

SK life science to Showcase Scientific Data at the 2019 American Academy of Neurology Annual Meeting

Feb 04, 2019

SK life science announces FDA acceptance of NDA submission for cenobamate, an investigational antiepileptic drug

Dec 03, 2018

SK life science presents new data on its lead investigational compound, cenobamate, at the American Epilepsy Society 2018 Annual Meeting

May 15, 2018

SK life science Awards Educational Grant to J. Kiffin Penry Epilepsy Education Programs in Support of Neurology Residents and Epilepsy Fellows

Apr 23, 2018

SK life science presents data on the investigational antiepileptic drug, cenobamate, at the American Academy of Neurology Annual Meeting 2018

Mar 06, 2018

SK life science to present data on cenobamate, an investigational antiepileptic compound, at ASCPT 2018 Annual Meeting

Nov 29, 2017

SK life science launches new corporate presence, expanded commercial operations in the United States